Videos

Insights from research on bloodstream infections with key attributions from study researcher Arden Baylink PhD.

The new Equity in Antimicrobial Stewardship Efforts (EASE) is a comprehensive set of priorities designed to overcome inequities and address the challenges with prescribing practices within the minoritized populations.

Insights from Dr. Md Zahidul Alam on treatments and prevention strategies for C difficile infection (CDI), supported by the CDC's recent study on CDI management in healthcare settings.

Photini Sinnis MD, professor at the Johns Hopkins School of Public Health and Deputy Director of the Johns Hopkins Malaria Research Institute, offers her expert insights into this zoonotic disease.

Danjuma Adda on WHO's efforts against Hepatitis B and his call for global vaccination and treatment efforts.

Dr. Thomas Holland discusses the breakthrough in antibiotic development.

In today’s world of sophisticated, complex tests, an evolving relationship between laboratory professionals and clinicians can aid in providing a quicker diagnosis and help to achieve better patient outcomes.

The company’s investigational vaccine, V116, is a conjugate vaccine and demonstrated immunogenicity for all 21 serotypes across the studied adult groups.

Insights from Jacob Teitelbaum MD on Long COVID Awareness Day.

Saskia Popescu PhD, MPH, MA, FAPIC on understanding the emergence of the origin for future pandemic preparedness, promoting global health security, and addressing long-term health impacts.

The impact of remdesivir across age groups.

The first-in-class entry inhibitor delivered therapeutic benefits over a long study period for patients with chronic infection.

Customizing treatment strategies for enhanced outcomes and longevity.

The therapy, lenacapavir, showed sustained virological suppression and safety over a 2-year period in this treatment-challenged patient population.

Novavax's Robert Walker, MD emphasizes protective health strategies highlighting the importance of COVID-19 vaccination for hypertensive individuals.

A new paper outlines how these variables can be connected to create situations where patients get less-than-optimal outcomes.

Investigators looked at potential risk factors as incidence rates changed over time after the introduction of COVID-19 and whether race and other variables affected the potential development of these infections.

How the development of antimicrobial stewardship programs can be an effective strategy for beginning to reduce this critical timing for patients in ICUs.

A recent novel study found reduced mortality rates in combining these therapies in patients being treated for this specific bacteremia.

A study showed utilizing a PCR-based test can narrow therapy quicker and help in resolving these infections sooner.

A small study showed high efficacy for the same strain of Pseudomonas aeruginosa.

With the FDA approval of 2 of these products, which are indicated for recurrent Clostridioides difficile infection (CDI), a study reviewed which types of clinicians are prescribing them and the protocols in using them.

Although the current reimbursement model makes it difficult for pharmaceutical companies to recoup their investments, a subscription model like the prospective congressional bill, the Pasteur Act, may help change that paradigm. In addition, there are international measures being carried out that may bring about changes.

The companies announced a licensing agreement on cefepime-taniborbactam.

The patient advocacy organization has events in place and is ready to launch its annual C diff awareness campaign.

A new study that went beyond the current standard of testing for the respiratory virus resulted in greater incidence rates and a truer accounting of case loads.

A clinician discusses the ongoing challenges presented with critically ill patients and the timing and scope of antibiotic prescribing practices.

A study presented at IDWeek details some of the shortfalls in utilization.

Codagenix is reporting data at this year’s IDWeek for its live-attenuated vaccine candidate, CoviLiv.

Social determinants such as housing and transportation were strong predictors of patients receiving fecal microbiota transplants (FMT).